Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantV
Venrock
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jul 12, 2026
Venrock is the venture manager whose own Encoded portfolio identifies investor Bryan Roberts.
Recorded funding activity
Encoded develops neurological gene therapies. Other recorded companies include Gitar’s software-review agents and Adcendo’s targeted cancer medicines. Venrock Healthcare Capital Partners remains a separate manager identity.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $275M 1 disclosed · full round size, not this investor’s share